Susan Wee

3.4k total citations
27 papers, 2.6k citations indexed

About

Susan Wee is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Susan Wee has authored 27 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Cell Biology. Recurrent topics in Susan Wee's work include Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (5 papers) and Endoplasmic Reticulum Stress and Disease (4 papers). Susan Wee is often cited by papers focused on Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (5 papers) and Endoplasmic Reticulum Stress and Disease (4 papers). Susan Wee collaborates with scholars based in United States, Germany and Switzerland. Susan Wee's co-authors include Dieter A Wolf, Christoph Lengauer, Rory Geyer, Chunshui Zhou, Alexander Kamb, Alice Loo, Frank Stegmeier, Scott Anderson, John R. Yates and Dmitri Wiederschain and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Molecular Cell.

In The Last Decade

Susan Wee

24 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Wee United States 16 2.1k 702 295 255 235 27 2.6k
Giordano Caponigro United States 22 2.0k 1.0× 674 1.0× 297 1.0× 183 0.7× 392 1.7× 46 2.7k
Jung-Sik Kim United States 26 1.5k 0.7× 596 0.8× 406 1.4× 232 0.9× 313 1.3× 45 2.2k
Michael R. Schlabach United States 19 3.1k 1.4× 757 1.1× 686 2.3× 340 1.3× 166 0.7× 27 3.8k
Peter M. Haverty United States 29 2.4k 1.1× 846 1.2× 677 2.3× 132 0.5× 351 1.5× 38 3.3k
Stuart D. Shumway United States 21 2.1k 1.0× 1.0k 1.4× 477 1.6× 416 1.6× 178 0.8× 29 2.7k
Stephen K. Tahir United States 22 2.4k 1.1× 980 1.4× 247 0.8× 245 1.0× 165 0.7× 35 3.3k
Nupam P. Mahajan United States 28 2.1k 1.0× 641 0.9× 305 1.0× 305 1.2× 531 2.3× 52 2.8k
Antonella Papa United States 18 2.4k 1.1× 855 1.2× 560 1.9× 193 0.8× 390 1.7× 29 3.1k
Péter Sandy United States 17 3.0k 1.4× 994 1.4× 429 1.5× 203 0.8× 203 0.9× 27 3.5k
Simona Mozzetti Italy 23 1.4k 0.7× 798 1.1× 403 1.4× 580 2.3× 226 1.0× 35 2.3k

Countries citing papers authored by Susan Wee

Since Specialization
Citations

This map shows the geographic impact of Susan Wee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Wee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Wee more than expected).

Fields of papers citing papers by Susan Wee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Wee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Wee. The network helps show where Susan Wee may publish in the future.

Co-authorship network of co-authors of Susan Wee

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Wee. A scholar is included among the top collaborators of Susan Wee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Wee. Susan Wee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chupak, Louis, Michael Wichroski, Xiaofan Zheng, et al.. (2023). Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization. ACS Medicinal Chemistry Letters. 14(7). 929–935. 10 indexed citations
2.
Chand, Saswati N., Michael Hansbury, Yvonne Lo, et al.. (2023). Abstract 1143: Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers. Cancer Research. 83(7_Supplement). 1143–1143. 8 indexed citations
3.
Gu, Junchen, Cindy Wang, Carolyn Cao, et al.. (2021). DGKζ exerts greater control than DGKα over CD8 + T cell activity and tumor inhibition. OncoImmunology. 10(1). 1941566–1941566. 10 indexed citations
4.
Hashimoto, Ayumi, Chan Gao, Jérôme Mastio, et al.. (2018). Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. Cancer Research. 78(19). 5644–5655. 43 indexed citations
5.
Hilton, John, Mihaela Cristea, Mark Voskoboynik, et al.. (2018). Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. Annals of Oncology. 29. viii134–viii134. 15 indexed citations
6.
Kirov, Stefan, Heshani Desilva, Jian Cao, et al.. (2015). Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression. Molecular Cancer Therapeutics. 14(10). 2167–2174. 72 indexed citations
7.
Wee, Susan, Haitao Li, Scott A. Armstrong, et al.. (2014). Targeting epigenetic regulators for cancer therapy. Annals of the New York Academy of Sciences. 1309(1). 30–36. 68 indexed citations
8.
Wee, Susan, Zainab Jagani, Kay X. Xiang, et al.. (2009). PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research. 69(10). 4286–4293. 354 indexed citations
9.
Schmidt, Michael, Philip R. McQuary, Susan Wee, Kay Hofmann, & Dieter A Wolf. (2009). F-Box-Directed CRL Complex Assembly and Regulation by the CSN and CAND1. Molecular Cell. 35(5). 586–597. 105 indexed citations
10.
Wee, Susan, Dmitri Wiederschain, Sauveur-Michel Maira, et al.. (2008). PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences. 105(35). 13057–13062. 411 indexed citations
11.
Wee, Susan, Christoph Lengauer, & Dmitri Wiederschain. (2008). Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. Current Opinion in Oncology. 20(1). 77–82. 14 indexed citations
12.
Kamb, Alexander, Susan Wee, & Christoph Lengauer. (2006). Why is cancer drug discovery so difficult?. Nature Reviews Drug Discovery. 6(2). 115–120. 264 indexed citations
13.
Wee, Susan, Rory Geyer, Takashi Toda, & Dieter A Wolf. (2005). CSN facilitates Cullin–RING ubiquitin ligase function by counteracting autocatalytic adapter instability. Nature Cell Biology. 7(4). 387–391. 156 indexed citations
14.
Zhou, Chunshui, Fatih Arslan, Susan Wee, et al.. (2005). PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes. BMC Biology. 3(1). 14–14. 110 indexed citations
15.
Geyer, Rory, Susan Wee, Scott Anderson, John R. Yates, & Dieter A Wolf. (2003). BTB/POZ Domain Proteins Are Putative Substrate Adaptors for Cullin 3 Ubiquitin Ligases. Molecular Cell. 12(3). 783–790. 266 indexed citations
16.
Wolf, Dieter A, Chunshui Zhou, & Susan Wee. (2003). The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases?. Nature Cell Biology. 5(12). 1029–1033. 156 indexed citations
17.
Zhou, Chunshui, Susan Wee, Edward K. Rhee, et al.. (2003). Fission Yeast COP9/Signalosome Suppresses Cullin Activity through Recruitment of the Deubiquitylating Enzyme Ubp12p. Molecular Cell. 11(4). 927–938. 148 indexed citations
18.
Wee, Susan, et al.. (2002). Conservation of the COP9/signalosome in budding yeast.. BMC Genetics. 3(1). 15–15. 58 indexed citations
19.
Wee, Susan, et al.. (2002). Conservation of the COP9/signalosome in budding yeast. BMC Genetics. 3(1). 9 indexed citations
20.
Bach, F H, et al.. (1982). Helper cell-independent cytotoxic T lymphocytes (HITc) in mouse and man.. The Mouseion at the JAXlibrary (Jackson Laboratory). 109. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giordano Caponigro Breakdown of academic impact, for papers by Jung-Sik Kim Breakdown of academic impact, for papers by Michael R. Schlabach Breakdown of academic impact, for papers by Peter M. Haverty Breakdown of academic impact, for papers by Stuart D. Shumway Breakdown of academic impact, for papers by Stephen K. Tahir Breakdown of academic impact, for papers by Nupam P. Mahajan Breakdown of academic impact, for papers by Antonella Papa Breakdown of academic impact, for papers by Péter Sandy Breakdown of academic impact, for papers by Simona Mozzetti
Rankless by CCL
2026